Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 6 records in total 6
    records per page




    Risk factors for adverse clinical outcomes in patients with COVID-19: A systematic review and meta-analysis

    Authors: Vanesa Bellou; Ioanna Tzoulaki; Evangelos Evangelou; Lazaros Belbasis

    doi:10.1101/2020.05.13.20100495 Date: 2020-05-19 Source: medRxiv

    Importance: COVID-19 is a clinically heterogeneous disease of varying severity and prognosis. Clinical characteristics that impact disease course could offer guidance for clinical decision making and future research endeavors and unveil disease pathways. Objective: To examine risk factors associated with adverse clinical outcomes in patients with COVID-19. Data sources: We performed a systematic review in PubMed from January 1 until April 19, 2020. Study selection: Observational studies that examined the association of any clinical characteristic with an adverse clinical outcome were considered eligible. We scrutinized studies for potential overlap. Data extraction and synthesis: Information on the effect of clinical factors on clinical endpoints of patients with COVID-19 was independently extracted by two researchers. When an effect size was not reported, crude odds ratios were calculated based on the available information from the eligible articles. Study-specific effect sizes from non-overlapping studies were synthesized applying the random-effects model. Main outcome and measure: The examined outcomes were severity and progression of disease, admission to ICU, need for mechanical ventilation, mortality, or a composite outcome. Results: We identified 88 eligible articles, and we performed a total of 256 meta-analyses on the association of 98 unique risk factors with five clinical outcomes. Seven meta-analyses presented the strongest epidemiological evidence in terms of statistical significance (P-value <0.005), between-study heterogeneity (I2 <50%), sample size (more than 1000 COVID-19 patients), 95% prediction interval excluded the null value, and absence of small-study effects. Elevated C-reactive protein (OR, 6.46; 95% CI, 4.85 - 8.60), decreased lymphocyte count (OR, 4.16; 95% CI, 3.17 - 5.45), cerebrovascular disease MESHD (OR, 2.84; 95% CI, 1.55 - 5.20), chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD (OR, 4.44; 95% CI, 2.46 - 8.02), diabetes mellitus HP diabetes mellitus MESHD (OR, 2.04; 95% CI, 1.54 - 2.70), hemoptysis HP (OR, 7.03; 95% CI, 4.57 - 10.81), and male TRANS sex (OR, 1.51; 95% CI, 1.30 - 1.75) were associated with risk of severe COVID-19. Conclusions and relevance: Our results highlight factors that could be useful for prognostic model building, help guide patients' selection for randomized clinical trials, as well as provide alternative treatment targets by shedding light to disease pathophysiology.

    Comparison of clinical characteristics and risk factors in hospitalized patients with SARS-CoV-2, MERS-CoV, and SARS-CoV infection MESHD

    Authors: Zhengtu Li; Xidong Wang; Guansheng Su; Zeguang Zheng; Shaoqiang Li; Yuwei Ye; Qiuxue Deng; Jinchuang Li; Xiaoyu Xiong; Xinguang Wei; Zeqiang Lin; Zichen Jie; Feng Ye

    doi:10.21203/rs.3.rs-28847/v1 Date: 2020-05-14 Source: ResearchSquare

    Herein, we compared the risk factors, clinical presentation of patients hospitalized with SARS-CoV-2, SARS-CoV MESHD, or MERS-CoV infection MESHD. Our data sources include PubMed, Embase, CNKI, and Ovid/Medline. The proportion of male TRANS patients with COVID-19 was higher than who with SARS but lower than who with MERS (p<0.001). More patients with COVID-19 had coexisting chronic medical conditions than those with SARS (p<0.001) but fewer than those with MERS (p<0.001), and the prevalence SERO of hypertension HP hypertension MESHD (17%) and smoking history (14%) was higher than in patients with SARS (p<0.001). Furthermore, the symptom of fever HP fever MESHD (53%), hemoptysis HP (1%), diarrhea HP diarrhea MESHD (4%) and vomiting HP vomiting MESHD (3%) of COVID-19 were significantly lower than that in patients with SARS or MERS. The level of ALT and AST in COVID-19 was significantly lower (p<0.001), however, thrombocytopenia HP thrombocytopenia MESHD, high LDH were common. Summary, male TRANS, smoking history and hypertension HP hypertension MESHD were the most common risk factors for hospitalization with COVID-19; and the clinical feature was less severe in COVID-19.

    Risk factors associated with fatal outcomes of novel coronavirus infection pneumonia MESHD pneumonia HP (COVID-19): A systematic review and meta-analysis

    Authors: Can Chen; Danying Yan; Yuqing Zhou; Guo Tian; Jie Wu; Xiaoxiao Liu; Chenyang Huang; Xiaofang Fu; Cheng Ding; Lei Lan; Chencheng Wang; Wei Wu; Robert Hecht; Changtai Zhu; Lanjuan Li; Shigui Yang

    doi:10.21203/rs.3.rs-23204/v1 Date: 2020-04-15 Source: ResearchSquare

    Background: The COVID-19 infection MESHD has caused 111652 deaths worldwide as of 13 April 2020. Risk factors for fatal outcomes of COVID-19 have varied across studies due to limited samples and have lacked effective qualitative and quantitative measurements. We performed a meta-analysis to evaluate risk factors for fatal outcomes of COVID-19.Methods: Data on demographic, clinic, laboratory findings and complications were extracted. Quantitative and qualitative synthesis was conducted for weighted-mean-difference (WMD) and odds-ratio (OR).Results: A total of 30 studies involving 5741 survivors and 1670 deaths were included. The death MESHD cases were significantly older than survivors (WMD=15.36, 95% CI: 12.90-17.82), male TRANS and smoking history showed higher risk to develop fatal outcome (OR=3.37, 95% CI: 2.27-5.01; OR=1.37, 95% CI: 1.02-1.83, respectively). The clinical symptoms including dyspnea HP dyspnea MESHD (OR=4.63, 95% CI: 2.85-7.54), hemoptysis HP (OR=3.11, 95% CI: 1.26-7.56), malaise (OR=2.44, 95% CI: 1.49-3.97). comorbidities with coronary heart disease MESHD (OR=4.36, 95% CI: 1.91-9.97), COPD MESHD (OR=3.70, 95% CI: 2.03-6.73) and cardiovascular disease MESHD (OR=3.45, 95% CI: 2.54-4.70). Compared to survivors, many laboratory indexes increased in deaths group, including serum SERO ferritin (WMD=741.47, 95% CI: 566.77-916.16), lactate dehydrogenase (WMD=226.86, 95% CI: 177.08-276.64) and myoglobin (WMD=102.58, 95% CI: 65.12-140.04), and the decreased indexes included PaO2/FiO2 (WMD=-71.61, 95% CI: -134.11 to -9.11), platelets (WMD=-41.09, 95% CI: -47.33 to -34.85) and PaO2 (WMD=-26.09, 95% CI: -38.9 to -13.29). Main complications contributed to the fatal outcome included sepsis HP sepsis MESHD (OR=184.61, 95% CI: 33.43-1019.42), shock HP shock MESHD (OR=133.76, 95% CI: 36.86-485.34) and respiratory failure HP respiratory failure MESHD (OR=47.37, 95% CI: 20.65-108.66). Conclusion: The main risk factors associated with fatal outcome of COVID-19 involved male TRANS, older age TRANS, smoking history, chronic medical conditions including coronary heart disease MESHD, COPD MESHD and cardiovascular disease MESHD, clinical symptoms including dyspnea HP dyspnea MESHD, hemoptysis HP hemoptysis MESHD and malaise, the increased laboratory indexes including serum SERO ferritin, lactate dehydrogenase and myoglobin, the decreased indexes including PaO2/FiO2, platelets and PaO2, main complications including sepsis HP sepsis MESHD, shock HP shock MESHD and respiratory failure HP respiratory failure MESHD. These factors could be considered in triaging patients and allocating medical resources when such medical resources are scarce, devising improved protocols for patient diagnosis and management, and developing new drugs and other therapies to treat COVID-19 patients.

    Comparison of clinical characteristics and risk factors in hospitalized patients with SARS-CoV-2, MERS-CoV, and SARS-CoV infection MESHD

    Authors: Zhengtu Li; Xidong Wang; Guansheng Su; Shaoqiang Li; Yuwei Ye; Qiuxue Deng; Jinchuang Li; Xiaoyu Xiong; Xinguang Wei; Zeqiang Lin; Zichen Jie; Feng Ye

    doi:10.21203/rs.3.rs-21414/v1 Date: 2020-04-05 Source: ResearchSquare

    Herein, we compared the risk factors, clinical presentation of patients hospitalized with  SARS-CoV-2, SARS-CoV MESHD, or MERS-CoV infection MESHD. The proportion of male TRANS patients with COVID-19 was higher than who with SARS but lower than who with MERS (p<0.001). More patients with COVID-19 had coexisting chronic medical conditions than those with SARS (p<0.001) but fewer than those with MERS (p<0.001), and the prevalence SERO of hypertension HP hypertension MESHD (17%) and smoking history (14%) was higher than in patients with SARS (p<0.001). Furthermore,the symptom of fever HP fever MESHD (53%), hemoptysis HP (1%), diarrhea HP diarrhea MESHD (4%) and vomiting HP vomiting MESHD (3%) of COVID-19 were significantly lower than that in patients with SARS or MERS. The level of ALT and AST in COVID-19 was significantly lower (p<0.001), however, thrombocytopenia HP thrombocytopenia MESHD, high LDH were common. Summary, male TRANS, smoking history and hypertension HP hypertension MESHD were the most common risk factors for hospitalization with COVID-19; and the clinical feature was less severe in COVID-19.

    A case report and summary of thrombocytopenia HP thrombocytopenia MESHD caused by coronavirus disease MESHD 2019

    Authors: Yibing Zhao; Na Du; Wei Li; Dongmei Xiang; Guodong Zhou; Ruixu Li; Panyang Xu; Jiancheng Xu

    doi:10.21203/rs.3.rs-20569/v1 Date: 2020-04-01 Source: ResearchSquare

    Background: Coronavirus disease 2019 has become a major problem for the world. We reported a representative case with thrombocytopenia HP thrombocytopenia MESHD.Case report: A 44-year-old female TRANS patient sought medical attention for fatigue HP fatigue MESHD and cough HP of 1 day duration. Thirteen days before disease onset, the patient had returned from Hubei province. Her body temperature on admission was 38.6℃. Blood SERO routine test showed a white blood SERO cell count of 4.0×109/L, lymphocyte count of 1×109/L, platelet count of 118×109/L, and C-reactive protein of 6.0mg/L. Lung computed tomography (CT) scan showed: large patches of ground-glass opacities at the posterior segment of the right upper lung lobe and bilaterally at the basal segment of the lower lung lobes. Her throat swabs tested positive for novel coronavirus nucleic acid. After antiviral and symptomatic treatment were given, on day 5 of hospitalization, her symptoms of coughing HP and chest pain HP chest pain MESHD worsened after coughing HP, and she also developed hemoptysis HP hemoptysis MESHD. Repeated lung CT scans showed that the lesion area had increased. The lymphocyte count had decreased to 0.55×109/L and the platelet count had decreased to 9×109/L on day 6. After a series of multimodal therapies were carried out, the patient’s platelet and lymphocyte count gradually increased to normal.Conclusion: We reported a COVID-2019 case with significant thrombocytopenia HP thrombocytopenia MESHD, which was more significantly decreased than in normal viral infections. However, the mechanism of thrombocytopenia HP thrombocytopenia MESHD is unknown and requires further research.

    Comparison of severe and non-severe COVID-19 pneumonia HP pneumonia MESHD: review and meta-analysis

    Authors: Weiping Ji; Jing Zhang; Gautam Bishnu; Xudong Du; Xinxin Chen; Hui Xu; Xiaoling Guo; Zhenzhai Cai; Xian Shen

    doi:10.1101/2020.03.04.20030965 Date: 2020-03-09 Source: medRxiv

    Objective: To compare the difference between severe and non-severe COVID-19 pneumonia HP pneumonia MESHD and figure out the potential symptoms lead to severity. Methods: Articles from PubMed, Embase, Cochrane database, and google up-to 24 February 2020 were systematically reviewed. Eighteen Literatures were identified with cases of COVID-19 pneumonia HP pneumonia MESHD. The extracted data includes clinical symptoms, age TRANS, gender TRANS, sample size and region et al were systematic reviewed and meta analyzed. Results: 14 eligible studies including 1,424 patients were analyzed. Symptoms like fever HP fever MESHD (89.2%), cough HP (67.2%), fatigue HP fatigue MESHD (43.6%) were common, dizziness MESHD, hemoptysis HP, abdominal pain HP abdominal pain MESHD and conjunctival congestion/ conjunctivitis HP conjunctivitis MESHD were rare. Polypnea/dyspnea MESHD dyspnea HP in severe patients were significantly higher than non-severe (42.7% vs.16.3%, P<0.0001). Fever HP Fever MESHD and diarrhea HP diarrhea MESHD were higher in severe patients(p=0.0374and0.0267). Further meta-analysis showed incidence of fever HP fever MESHD(OR1.70,95%CI 1.01-2.87), polypnea/dyspnea MESHD dyspnea HP(OR3.53, 95%CI 1.95-6.38) and diarrhea HP diarrhea MESHD(OR1.80,95%CI 1.06-3.03) was higher in severe patients, which meant the severe risk of patients with fever HP fever MESHD, polypnea/dyspnea MESHD dyspnea HP, diarrhea HP diarrhea MESHD were 1.70, 3.53, 1.80 times higher than those with no corresponding symptoms. Conclusions: Fever HP Fever MESHD, cough HP cough MESHD and fatigue HP fatigue MESHD are common symptoms in COVID-19 pneumonia HP pneumonia MESHD. Compared with non-severe patients, the symptoms as fever HP fever MESHD, polypnea/dyspnea and diarrhea MESHD dyspnea HP and diarrhea HP are potential symptoms lead to severity.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.